<DOC>
	<DOCNO>NCT01282632</DOCNO>
	<brief_summary>Atypical neuroleptic may antidepressant quality bipolar depression unipolar depression . Some data support use Risperidone Olanzapine , direct comparison relative efficacy tolerability treatment resistant depression . The current study design pilot study examine efficacy tolerability Olanzapine vs. Risperidone add fail serotonin re-uptake inhibitor ( SSRI ) depression .</brief_summary>
	<brief_title>Risperidone vs. Olanzapine add-on Treatment Treatment Resistant Depression</brief_title>
	<detailed_description>Overview Study Design This Canadian , multicentre , double blind , comparator trial 42 patient TRD . TRD define failure respond adequately two successive course different antidepressant adequate dose ( least fluoxetine 20 mg , citalopram 20 mg , paroxetine 20 mg , sertraline 100 mg , fluvoxamine 150 mg , venlafaxine 225 mg ) ) least 4 week . All subject , entry study currently respond treatment least 4 week duration serotonin re-uptake inhibitor ( SSRI ) selective nor-epinephrine serotonin re-uptake inhibitor ( SNRI ) . Non-response define score 3 ( `` minimal improvement '' ) bad Clinical global Impression Improvement . The objective ass appropriateness trial design determine sample size requirement future control trial . In addition efficacy safety oral dos risperidone ( .5-3 mg/day ) olanzapine ( 2.5-15 mg.day ) add-on therapy SSRI SNRI treatment resistant depression evaluate . Subjects meet screen criterion enter 6-week trial risperidone olanzapine add current SSRI SNRI therapy . A medical/ psychiatric history , HAM-D-29 ( first 17 item use outcome ) , MADRS HAM-A obtain screen . At subsequent visit HAM-D , HAM-A , MADRS perform adverse event ( spontaneous use CASES checklist ) concomitant medication collect . Recruitment : Subjects draw two source : 1 . Outpatients currently attend clinic site . These subject already treatment may refer local community clinic involve study consultation . Should subject drop complete study receive treatment usual site . 2 . Advertisements . Advertisements place local medium ( radio , television , newspaper ) identifying nature study provide contact number . These advertisement approve local IRB 's prior posting .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Depressive Disorder , Treatment-Resistant</mesh_term>
	<mesh_term>Serotonin</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<criteria>Subjects meet follow criterion eligible trial : 1 . Male female outpatient ; 2 . Aged 18 65 year ( extremes include ) ; 3 . Subjects suffer current episode nonpsychotic , unipolar depression determine depression section SCIDIV . 4 . Subjects treatment resistant depression define failure respond two successive course monotherapy give adequate dos minimum 4 week different antidepressant ( current course antidepressant consider second failed course ) ; 5 . Subjects currently take SSRI SNRI least 4 week , adequate dosage responding , define score 3 CGII . dose change 2 week prior entry . 6 . A minimum score 16 17 item HAMD 7 . Ability provide inform consent . Subjects meet one follow criterion select : 1 . Subjects actively suicidal determine score 3 suicide item HAMD opinion treat physician ; 2 . Other current ( active symptomatology within last 2 month ) Axis I DSM IV diagnosis nicotine caffeine dependence Anxiety disorder . 3 . Use disallow concomitant therapy ; psychotropic medication except occasional benzodiazepine . ( See `` Rescue Medication '' ) ; 4 . History alcohol drug abuse dependence , within 3 month entry trial ) ; 5 . Seizure disorder require medication ; 6 . Active medical condition require urgent attention would contraindicate use risperidone olanzapine . For example stable thyroid disease asthma would acceptable , whereas acute hepatitis would ; 7 . Participation investigational drug trial within 30 day prior start trial 8 . Known sensitivity risperidone , olanzapine antidepressant ; 9 . History neuroleptic malignant syndrome ( NMS ) ; 10 . Subjects imminent risk injury self others , cause significant damage property , judge investigator ; 11 . Female subject pregnant breastfeeding ; 12 . Female subject childbearing potential without adequate contraception ( sterilization , barrier , IUD , oral contraceptive , intramuscular subdermal administration depotprogestagens ) ; 15 . Previous exposure risperidone olanzapine current episode .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>depression</keyword>
	<keyword>treatment resistant depression</keyword>
	<keyword>unipolar</keyword>
	<keyword>non- psychotic major depression</keyword>
	<keyword>add-on serotonin type antidepressant</keyword>
	<keyword>risperidone</keyword>
	<keyword>olanzapine</keyword>
	<keyword>double blind comparison</keyword>
	<keyword>randomize</keyword>
</DOC>